ArticleNPJ science of food2025
Stability and iron affinity of Donkey-hide gelatin hydrolysates: Implications for improving iron bioavailability and gut microbiota modulation.
Article in NPJ science of food, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Iron deficiency anemia (IDA) is a prevalent nutritional disorder primarily treated with inorganic iron supplements. However, these interventions are often limited by poor bioavailability and gastrointestinal side effects. Food-derived protein hydrolysates have emerged as promising dietary strategies to enhance iron absorption and mitigate adverse effects. This study evaluated the efficacy of dietary supplementation with Donkey-hide gelatin hydrolysates (DH) in alleviating IDA in a rat model. DH-Fe exhibited superior binding affinity and stability, retaining more soluble iron fraction under diverse conditions, confirming its role as a functional dietary iron carrier. In vivo, DH markedly enhanced hematopoiesis and iron homeostasis, elevating hemoglobin by 44% and normalizing serum ferritin (25.34 ng/mL). DH also enhanced antioxidant defenses, increasing SOD and hydroxyproline levels to 111% and 168% of the reference groups, respectively. Moreover, DH ameliorated IDA-induced liver injury and gut microbiota dysbiosis by promoting beneficial bacteria (e.g., Ruminococcus) and suppressing pathogenic bacteria (e.g., Escherichia-Shigella). Overall, these findings indicate that DH improves hematopoiesis and modulates gut microbiota composition, supporting its potential as a next-generation dietary iron supplement for IDA management.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.